SG Americas Securities
PTGX icon

SG Americas Securities’s Protagonist Therapeutics PTGX Stock Holding History

SG Americas Securities’s Portfolio PTGX Stock Details PTGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.34M Buy
19,080
+983
+5% +$103K ﹤0.01% 1430
2026
Q1 		$1.91M Sell
18,097
-1,900
-10% -$168K ﹤0.01% 1420
2025
Q4 		$1.75M Sell
19,997
-21,249
-52% -$1.74M ﹤0.01% 1615
2025
Q3 		$2.74M Buy
41,246
+39,322
+2,044% +$2.24M 0.01% 787
2025
Q2 		$106K Buy
+1,924
New +$92.3K ﹤0.01% 2616
2024
Q4 		– Sell
-25,740
Closed -$1.16M – 3523
2024
Q3 		$1.16M Buy
25,740
+14,789
+135% +$598K ﹤0.01% 974
2024
Q2 		$379K Buy
+10,951
New +$321K ﹤0.01% 1830
2023
Q3 		– Sell
-195,756
Closed -$5.41M – 3225
2023
Q2 		$5.41M Buy
195,756
+177,241
+957% +$4.44M 0.04% 337
2023
Q1 		$426K Sell
18,515
-38,606
-68% -$648K 0.01% 1838
2022
Q4 		$623K Sell
57,121
-43,079
-43% -$363K 0.01% 1351
2022
Q3 		$845K Sell
100,200
-52,833
-35% -$500K 0.01% 1129
2022
Q2 		$1.21M Buy
153,033
+120,074
+364% +$1.45M 0.01% 1127
2022
Q1 		$780K Sell
32,959
-5,591
-15% -$158K 0.01% 1597
2021
Q4 		$1.32M Buy
38,550
+19,184
+99% +$606K 0.01% 1435
2021
Q3 		$343K Buy
19,366
+16,556
+589% +$706K ﹤0.01% 2822
2021
Q2 		$126K Sell
2,810
-5,915
-68% -$195K ﹤0.01% 2542
2021
Q1 		$226K Buy
+8,725
New +$221K ﹤0.01% 2599
2020
Q4 		– Sell
-5,420
Closed -$106K – 3444
2020
Q3 		$106K Sell
5,420
-6,844
-56% -$128K ﹤0.01% 2442
2020
Q2 		$217K Buy
+12,264
New +$154K ﹤0.01% 2793

Other funds holding PTGX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

SG Americas Securities's PTGX Position: Q2 2026 in Review

SG Americas Securities increased its Protagonist Therapeutics (PTGX) stake by 5.4% in Q2 2026, buying an estimated $103K and bringing the position to 19,080 shares worth $2.34M. The position accounts for ﹤0.01% of the portfolio, ranked #1430.

SG Americas Securities first reported a position in PTGX in Q2 2020 and has held it in 19 quarters since. The position peaked at $5.41M in Q2 2023. 343 funds tracked by Wall St. Rank hold PTGX as of Q2 2026.

  • SG Americas Securities held 19,080 shares of Protagonist Therapeutics worth $2.34M as of Q2 2026.
  • SG Americas Securities bought 983 Protagonist Therapeutics shares in Q2 2026, an estimated $103K.
  • Protagonist Therapeutics made up ﹤0.01% of SG Americas Securities's portfolio in Q2 2026, its #1430 holding.
  • SG Americas Securities first reported a position in Protagonist Therapeutics in Q2 2020 and has held it in 19 quarters since.
  • SG Americas Securities's Protagonist Therapeutics position peaked at $5.41M in Q2 2023.
  • 343 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q2 2026.

Based on SG Americas Securities's 13F filing for Q2 2026, filed 7 Aug 2026.